Board to approve September 2026 quarterly results

EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.2%Reaction day

₹218.50

prior close

₹215.68

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-2.2% vs market

Pharmaceuticals peers, median of 170sector-0.5%-2.8% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.0

15m

-0.5

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.2-1.0-2.2-0.5-2.8

Next day

-3.3-3.3+0.0-2.2-1.1

+2.5-2.9+5.4-1.1+3.6

+2.7-1.3+4.0+0.7+2.1

+8.1-1.2+9.3+1.9+6.2

+1.4-0.5+1.9+2.1-0.8

-1.7-1.6-0.0+1.0-2.7

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on October 28, 2026 to approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. The trading window remains closed until October 30, 2026. No financial figures are provided yet.

Likely market impact

A quarterly results update is pending and may affect the share price when published. Trading remains closed until October 30, 2026.

By the numbersStandalone · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹81.38 Cr	₹74.47 Cr	+9.3%
Operating profit	₹14.83 Cr	₹13.78 Cr	+7.6%
Profit after tax	₹12.59 Cr	₹12.57 Cr	+0.1%
EBITDA margin	20.3%	22.1%	−1.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.